Search research articles
Contact Us
Filters
Showing results (21-30 of 52) with videos related to
Page
of 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 27, 2023
FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Ashley Woods, Kelly J Norsworthy, Xin Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 28, 2025
FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD
Kelly J Norsworthy, Donna R Rivera, Joseph Wynne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 18, 2022
FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes
Nina Kim, Kelly J Norsworthy, Sriram Subramaniam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 23, 2023
Considerations for Drug Development in Myelodysplastic Syndromes
Mikkael A Sekeres, Nina Kim, Amy E DeZern, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 19, 2023
FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and Ethnicity
Dianne Pulte, Laura Fernandes, Guo Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2021
FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
E Dianne Pulte, Kelly J Norsworthy, Yaping Wang, et al.
JAMA Oncology
|
August 29, 2024
Externally Controlled Studies Using Real-World Data in Patients With Hematological Cancers: A Systematic Review
Sjoerd J F Hermans, Niek G van der Maas, Yvette van Norden, et al.
The Oncologist
|
May 31, 2022
FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial
E Dianne Pulte, Haiyan Chen, Lauren S L Price, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 24, 2022
FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy
Emily Y Jen, Xin Wang, Meng Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2020
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis
Kelly J Norsworthy, Flora Mulkey, Emma C Scott, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 52) with videos related to
Sort By:
Page
of 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 27, 2023
FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Ashley Woods, Kelly J Norsworthy, Xin Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 28, 2025
FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD
Kelly J Norsworthy, Donna R Rivera, Joseph Wynne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 18, 2022
FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes
Nina Kim, Kelly J Norsworthy, Sriram Subramaniam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 23, 2023
Considerations for Drug Development in Myelodysplastic Syndromes
Mikkael A Sekeres, Nina Kim, Amy E DeZern, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 19, 2023
FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and Ethnicity
Dianne Pulte, Laura Fernandes, Guo Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2021
FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
E Dianne Pulte, Kelly J Norsworthy, Yaping Wang, et al.
JAMA Oncology
|
August 29, 2024
Externally Controlled Studies Using Real-World Data in Patients With Hematological Cancers: A Systematic Review
Sjoerd J F Hermans, Niek G van der Maas, Yvette van Norden, et al.
The Oncologist
|
May 31, 2022
FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial
E Dianne Pulte, Haiyan Chen, Lauren S L Price, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 24, 2022
FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy
Emily Y Jen, Xin Wang, Meng Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2020
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis
Kelly J Norsworthy, Flora Mulkey, Emma C Scott, et al.
Page
of 6